Phase 3 Keynote 522 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phase 3 keynote 522 trial . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phase 3 Keynote 522 Trial Today - Breaking & Trending Today

Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC

Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer. ....

Peter Schmid , P Ann Onc , Centre Of Experimental Cancer Medicine , Barts Cancer Institute , Barts Breast Cancer Centre , Experimental Cancer Medicine , New England Journal , Early Triple Negative Breast , Esmo Congress , Breast Cancer , Phase 3 Keynote 522 Trial ,